TNFRSF8 and anaplastic large cell lymphoma: Additionally, the anti-CC chemokine receptor 4 monoclonal antibody mogamulizumab was approved in Japan for treatment of anti-CC chemokine receptor 4-positive relapsed/refractory PTCL [14], and the anti-CD30 antibody-drug conjugate brentuximab vedotin was approved for treatment of relapsed/refractory ALCL [15, 16].